Literature DB >> 22684375

Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.

Stepan Vesely1, Ladislav Jarolim, Marek Schmidt, Ivo Minarik, Pavel Dusek, Marko Babjuk.   

Abstract

PURPOSE: Contemporary tools estimating increased risk of prostate cancer (PCa) relapse after radical prostatectomy (RP) are far from perfect and there has been an intensive search for additional predictive variables. We aimed to explore whether the parameters of postoperative ultrasensitive prostate-specific antigen (PSA) decline provide additional information for predicting PCa progression.
METHODS: A total of 319 consecutive men, with at least 2 years of follow-up after RP for clinically localized PCa were subjected to this study. Intensive postoperative measurements of ultrasensitive PSA resulted in total of 4028 PSA values available for statistical evaluation. Biochemical recurrence (BCR) was defined as PSA ≥0.2 ng/ml. The accuracy of predictive models was quantified with the area under the curve.
RESULTS: Over a median follow-up of 43 months (24-99 months), 107 patients (34%) experienced BCR after RP. In patients with BCR, significantly higher values of PSA nadir (p < 0.001) and a decreased time interval from surgery to reach PSA nadir (p < 0.001) were observed. A multivariable Cox regression model confirmed that PSA nadir >0.01 ng/ml (HR 6.01, 95% CI: 3.89-9.52) and time to PSA nadir <3 months (HR 2.86, 95% CI: 1.74-5.01) were independent predictors of BCR. The inclusion of PSA nadir and the time to PSA nadir into the model resulted in improvement of predictive accuracy by 16% over the model designed on the basis of established parameters.
CONCLUSIONS: Our results demonstrate that the level of PSA nadir and the time to PSA nadir determined by ultrasensitive assay significantly improve the identification of patients who are at high risk of disease recurrence after RP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684375     DOI: 10.1007/s00345-012-0892-3

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  20 in total

Review 1.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

2.  Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.

Authors:  Samson Shen; Herbert Lepor; Robert Yaffee; Samir S Taneja
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

4.  Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.

Authors:  Sung Kyu Hong; Hong Zoo Park; Won Ki Lee; Dae Sung Kim; June Suk Lee; Seung Hwan Doo; Seong Jin Jeong; Cheol Yong Yoon; Seok-Soo Byun; Sang Eun Lee
Journal:  Urology       Date:  2010-07-01       Impact factor: 2.649

Review 5.  Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.

Authors:  Matthew N Simmons; Andrew J Stephenson; Eric A Klein
Journal:  Eur Urol       Date:  2007-01-12       Impact factor: 20.096

6.  Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer.

Authors:  Felix K-H Chun; Markus Graefen; Mario Zacharias; Alexander Haese; Thomas Steuber; Thorsten Schlomm; Jochen Walz; Pierre I Karakiewicz; Hartwig Huland
Journal:  World J Urol       Date:  2006-02-28       Impact factor: 4.226

7.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

8.  Predicting life expectancy in men with clinically localized prostate cancer.

Authors:  Mark E Cowen; Lakshmi K Halasyamani; Michael W Kattan
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

Review 9.  Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.

Authors:  Leonard G Gomella; Ilia Zeltser; Richard K Valicenti
Journal:  Urology       Date:  2003-12-29       Impact factor: 2.649

10.  Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.

Authors:  Shahrokh F Shariat; Jose A Karam; Jochen Walz; Claus G Roehrborn; Francesco Montorsi; Vitaly Margulis; Fred Saad; Kevin M Slawin; Pierre I Karakiewicz
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

View more
  6 in total

1.  Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.

Authors:  Stephanie L Skove; Lauren E Howard; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Daniel M Moreira; Stephen J Freedland
Journal:  Urology       Date:  2017-07-19       Impact factor: 2.649

2.  Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up.

Authors:  Nikolaos Grivas; Daan de Bruin; Kurdo Barwari; Erik van Muilekom; Corinne Tillier; Pim J van Leeuwen; Esther Wit; Wouter Kroese; Henk van der Poel
Journal:  J Clin Lab Anal       Date:  2018-10-26       Impact factor: 2.352

3.  Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.

Authors:  Hitoshi Inoue; Kensaku Nishimura; Seiji Yamaguchi; Norio Nonomura; Tsuneo Hara
Journal:  Int J Clin Oncol       Date:  2014-03-21       Impact factor: 3.402

4.  Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.

Authors:  Alexander W Pastuszak; Amy M Pearlman; Win Shun Lai; Guilherme Godoy; Kumaran Sathyamoorthy; Joceline S Liu; Brian J Miles; Larry I Lipshultz; Mohit Khera
Journal:  J Urol       Date:  2013-02-08       Impact factor: 7.450

5.  Metabolism of Immune Cells in the Tumor Microenvironment.

Authors:  Jin G Jung; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  The significance of reporting to the thousandths place: Figuring out the laboratory limitations.

Authors:  Joely A Straseski; Casey Whale; Andrew Wilson; Frederick G Strathmann
Journal:  Pract Lab Med       Date:  2016-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.